This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

BenzingaNov 25 08:58 ET

Needham Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsNov 25 07:31 ET · Ratings

Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target

BenzingaNov 25 06:56 ET · Ratings

TD Cowen Initiates Viridian Therapeutics(VRDN.US) With Buy Rating

Moomoo NewsNov 25 06:33 ET · Ratings

TD Cowen Initiates Coverage On Viridian Therapeutics With Buy Rating

BenzingaNov 25 06:09 ET

Viridian Therapeutics: Buy Rating Due to Promising TED Therapy and Market Potential

TipRanksNov 25 06:06 ET · Ratings